The use of flow diverting stents in the treatment of intracranial aneurysms is associated with arisk of neurological morbidity due to their thrombogenicity. To reduce this risk different surface modifications have been developed. The Derivo2 Embolization Device (Acandis, Pforzheim, Germany) has proven to be asafe and effective flow diverter. To overcome the risk of thrombo-embolism, the device was modified by adding an anti-thrombogenic fibrin-heparin coating. We aimed to assess the safety and effectiveness of the Derivo2 heal Embolization Device. Retrospective multicenter data from nine German neurovascular centers between February 2022 until December 2023 were used. Patients treated with the Derivo2 heal Embolization Device for unruptured or ruptured intracranial aneurysms were included. Peri- and postprocedural adverse events, clinical outcomes, and angiographic follow-up results were evaluated. 84patients (73.8% female; mean age58.7 years) with 89aneurysms (mean size 9.8 mm) were included. 87.6% were located in the anterior circulation. Most of them were sidewall aneurysms (88.8%). 96flow diverters were used. 99.0% were successfully implanted. An in-stent balloon angioplasty was performed in 6.0% of the cases. An additional coiling was performed in 28.6%. Technical difficulties were present in 12.0% of the cases. Thrombotic events occurred in 4.8% with no neurological sequelae. Mortality and morbidity were 0 and 1.2% respectively. Adequate aneurysm occlusion was achieved in 80.7% with amean follow-up time of 6.6months. The Derivo2 heal Embolization Device showed asatisfying aneurysm occlusion and safety with alow rate of neurological morbidity.